Showing results (121-130 of 143) with videos related to
Sort By:
Pageof 15
Arthritis Research & Therapy|March 31, 2017
DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritisWeida Meng, Zaihua Zhu, Xia Jiang, et al.Annals of the Rheumatic Diseases|May 23, 2025
Spatial multiomics decipher fibroblast-macrophage dynamics in systemic sclerosisZhijian Li, Aleix Rius Rigau, Wenjie Xie, et al.Oncotarget|December 22, 2017
Elevated serum urate is a potential factor in reduction of total bilirubin: a Mendelian randomization studyHui Zhang, Jing Liu, Zheng Dong, et al.Annals of the Rheumatic Diseases|October 21, 2018
HLA class I and II alleles in susceptibility to ankylosing spondylitisJohn D Reveille, Xiaodong Zhou, MinJae Lee, et al.Innovation (Cambridge (Mass.))|August 15, 2025
Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trialYu Xue, Tianshu Chu, Jiankang Hu, et al.The Journal of Rheumatology|April 3, 2016
Copy Number Variation of HLA-DQA1 and APOBEC3A/3B Contribute to the Susceptibility of Systemic Sclerosis in the Chinese Han PopulationShicheng Guo, Yuan Li, Yi Wang, et al.Advances in Therapy|May 19, 2026
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 TrialZaihua Zhu, Yu Xue, Tianshu Chu, et al.Rheumatology and Therapy|August 20, 2025
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority TrialNing Kong, Yu Xue, Li Mao, et al.Scientific Reports|March 3, 2018
Genetic variants in two pathways influence serum urate levels and gout risk: a systematic pathway analysisZheng Dong, Jingru Zhou, Xia Xu, et al.Plos One|September 4, 2014
Association of the HLA-DRB1 with scleroderma in Chinese populationDongyi He, Jiucun Wang, Lin Yi, et al.Pageof 15